Related Experiment Video
Updated: Aug 23, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Microenvironment factors do not afford myeloma cell lines protection from simvastatin
Alla Osadchy1, Liat Drucker, Judith Radnay
1Oncogenetic Laboratory, Sapir Medical Center, Meir Hospital, Kfar Sava, Israel.
Background:
The intensive interactions of myeloma cells (multiple myeloma, MM) with microenvironmental components of the bone marrow contribute significantly to their proliferation and survival. It has been shown that these signals confer drug resistance, delineating their circumvention as a primary objective in disease treatment. This study was designed to assess the effect of some major extracellular factors on the previously established anti-neoplastic response of myeloma cells to simvastatin (Sim).
Study Design:
RPMI8226, U266, and ARH77 seeded in culture plates precoated with fibronectin (FN)/agarose/none were treated with Sim, insulin-like growth factor-I (IGF-I), interleukin-6 (IL-6) or combinations for 5 d. Then we assessed cell morphology, viability (WST1), cell cycle (propidium iodide, PI, staining and flow cytometric analysis), total cell count, and cell death (trypan blue exclusion), and DNA fragmentation.
Results And Conclusions:
Reduced viability was demonstrated with Sim in all treated cell lines with and without co-administration of IGF-I or IL-6 (P < 0.05). The extent of inhibition did not vary between Sim only and combinations (NS). FN did not influence cell response to Sim alone or combined with IL-6/IGF-I (NS). We conclude that IL-6, IGF-I, and FN do not afford myeloma cell lines protection from Sim modulation.
Insights
Simvastatin effectively reduces multiple myeloma cell viability, even when exposed to bone marrow microenvironment factors like IGF-I, IL-6, and fibronectin. These factors do not protect myeloma cells from simvastatin
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Multiple myeloma (MM) cell proliferation and survival are significantly influenced by bone marrow microenvironment interactions.
- These microenvironmental signals can confer drug resistance, making their circumvention a key therapeutic goal.
- Simvastatin (Sim) has demonstrated anti-neoplastic effects on myeloma cells.
Purpose of the Study:
- To evaluate the impact of key extracellular factors on the anti-neoplastic activity of simvastatin against multiple myeloma cells.
- To determine if insulin-like growth factor-I (IGF-I), interleukin-6 (IL-6), or fibronectin (FN) can alter the response of myeloma cells to simvastatin.
Main Methods:
- Multiple myeloma cell lines (RPMI8226, U266, ARH77) were cultured on fibronectin-coated plates or uncoated surfaces.
- Cells were treated with simvastatin alone or in combination with IGF-I, IL-6, or both for 5 days.
- Assessed outcomes included cell morphology, viability (WST1 assay), cell cycle progression (propidium iodide staining), cell count, cell death (trypan blue exclusion), and DNA fragmentation.
Main Results:
- Simvastatin significantly reduced viability in all tested myeloma cell lines.
- Co-administration of IGF-I or IL-6 did not alter the extent of simvastatin-induced viability reduction.
- Fibronectin did not influence the response of myeloma cells to simvastatin, either alone or in combination with other factors.
Conclusions:
- Interleukin-6, insulin-like growth factor-I, and fibronectin do not provide protection to multiple myeloma cell lines against simvastatin.
- Simvastatin demonstrates consistent anti-myeloma activity irrespective of these common bone marrow microenvironmental components.
- These findings suggest simvastatin's potential as a therapeutic agent for multiple myeloma, independent of certain protective microenvironmental factors.
